TABLE 1.
1086.C gp140 binding to CD4i epitope-specific MAb 17B in the absence or presence of various C1-specific antibodies and control antibodiesa
| Antibody | 17B binding response (RU) | % upregulation |
|---|---|---|
| None | 357 ± 37 | 0.0 |
| Synagis | 363 ± 38 | 1.8 |
| A32 | 636 ± 40 | 78.3 |
| CH29 | 386 ± 24 | 8.1 |
| CH38 | 756 ± 44 | 111.9 |
| CH40 | 361 ± 39 | 1.2 |
| CH51 | 408 ± 44 | 14.4 |
| CH52 | 430 ± 48 | 20.5 |
| CH54 | 474 ± 51 | 32.9 |
| CH77 | 358 ± 24 | 0.3 |
| CH78 | 292 ± 37 | −17.9 |
| CH81 | 433 ± 47 | 21.5 |
| CH89 | 477 ± 53 | 33.7 |
| CH90 | 358 ± 38 | 0.5 |
| CH91 | 633 ± 65 | 77.5 |
| CH92 | 362 ± 38 | 1.6 |
| CH94 | 382 ± 26 | 7.2 |
| CH29 IgA2 | 369 ± 22 | 3.6 |
| CH38 IgA2 | 673 ± 41 | 88.7 |
The 17B binding experiment was performed, and the percent upregulation was calculated as described in Materials and Methods. An average of three measurements of 17B binding and the estimated standard deviations are shown.